|
|
|
|
| LEADER |
04261nmm a2200301 u 4500 |
| 001 |
EB000668737 |
| 003 |
EBX01000000000000000521819 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783642656781
|
| 100 |
1 |
|
|a Sartorelli, Alan C.
|
| 245 |
0 |
0 |
|a Antineoplastic and Immunosuppressive Agents
|h Elektronische Ressource
|b Part I
|c by Alan C. Sartorelli, David G. Johns
|
| 250 |
|
|
|a 1st ed. 1974
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 1974, 1974
|
| 300 |
|
|
|a XXIV, 764 p
|b online resource
|
| 505 |
0 |
|
|a I Table of Contents -- Section A: General Considerations: Antineoplastic Agents -- 1 Agents of Choice in Neoplastic Disease -- 2 Evaluation of Antineoplastic Activity: Requirements of Test Systems -- 3 Rational Design of Alkylating Agents -- 4 Rational Design of Folic Acid Antagonists -- 5 Rational Design of Purine Nucleoside Analogs -- 6 Rational Design of Pyrimidine Nucleoside Analogs -- 7 Basic Concepts of Cell Population Kinetics -- 8 Clinical Applications of Cell Cycle Kinetics -- 9 Metabolic Events in the Regulation of Cell Reproduction -- 10 Site of Action of Cytotoxic Agents in the Cell Life Cycle -- 11 Pharmacokinetic Models for Antineoplastic Agents -- 12 Absorption, Distribution, and Excretion of Antineoplastic and Immunosuppressive Agents -- 13 Transport of Antineoplastic Agents -- 14 Metabolism of Cancer Chemotherapeutic Agents via Pathways Utilized by Endogenous Substrates -- 15 Metabolism of Cancer Chemotherapeutic Agents via Pathways Utilized by Xenobiotics -- 16 Theoretical Considerations in the Chemotherapy of Brain Tumors -- 17 The Constancy of the Product of Concentration and Time -- 18 Biochemical Aspects of Selective Toxicity -- 19 Mechanisms of Resistance -- 20 Combination Chemotherapy: Basic Considerations -- 21 Combination Chemotherapy: Clinical Considerations -- 22 Tests Predictive of Cytotoxic Activity -- 23 Metabolic Changes Induced by Ionizing Radiations -- 24 Radiation Research: Survival Kinetics -- 25 Clinical and Laboratory Investigation of Combination Radiation and Chemical Therapy -- 26 Tumor Immunotherapy -- Section B: General Considerations: Immunosuppressive Agents -- 27 Evaluation of Immunosuppressive Agents -- 28 Immunosuppressive Agents -- 29 Clinical Utility of Immunosuppressive Agents -- Author Index
|
| 653 |
|
|
|a Medical sciences
|
| 653 |
|
|
|a Pharmacy
|
| 653 |
|
|
|a Health Sciences
|
| 700 |
1 |
|
|a Johns, David G.
|e [author]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Handbook of Experimental Pharmacology
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-65678-1
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-65678-1?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Over the past two decades a number of attempts have been made, with varying degrees of success, to collect in a single treatise available information on the basic and applied pharmacology and biochemical mechanism of action of antineoplastic and immunosuppressive agents. The logarithmic growth of knowledge in this field has made it progressively more difficult to do justice to all aspects of this topic, and it is possible that the present handbook, more than four years in preparation, may be the last attempt to survey in a. single volume the entire field of drugs em ployed in cancer chemotherapy and immunosuppression. Even in the present instance, it has proved necessary for practical reasons to publish the material in two parts, although the plan of the work constitutes, at least in the editors' view, a single integrated treatment of this research area. A number of factors have contributed to the continuous expansion of research in the areas of cancer chemotherapy and immunosuppression. Active compounds have been emerging at ever-increasing rates from experimental tumor screening systems maintained by a variety of private and governmental laboratories through out the world. At the molecular level, knowledge of the modes of action of estab lished agents has continued to expand, and has permitted rational drug design to playa significantly greater role in a process which, in its early years, depended almost completely upon empirical and fortuitous observations
|